

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
4.0	2025/04/14	801078-00020	Date of first issue: 2016/07/15

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Orbifloxacin Solid Formulation

Manufacturer or supplier's details

Company : MSD

Address : No. 485 Jing Tai Road
Pu Tuo District - Shanghai - China 200331

Telephone : +1-908-740-4000

Emergency telephone number : 86-571-87268110

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Emergency Overview


Appearance	: powder
Colour	: No data available
Odour	: No data available

Suspected of damaging the unborn child.

GHS Classification

Reproductive toxicity : Category 2

GHS label elements

Hazard pictograms : 

Signal word : Warning

Hazard statements : H361d Suspected of damaging the unborn child.

Precautionary statements : **Prevention:**
P203 Obtain, read and follow all safety instructions before use.
P280 Wear protective gloves/ protective clothing/ eye protec-

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
4.0	2025/04/14	801078-00020	Date of first issue: 2016/07/15

tion/ face protection/ hearing protection.

Response:

P318 IF exposed or concerned, get medical advice.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Physical and chemical hazards

Not classified based on available information.

Health hazards

Suspected of damaging the unborn child.

Environmental hazards

Not classified based on available information.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Orbifloxacin	113617-63-3	≥ 3 -< 10
Magnesium stearate	557-04-0	≥ 1 -< 10

4. FIRST AID MEASURES

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
4.0	2025/04/14	801078-00020	Date of first issue: 2016/07/15

If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation. Suspected of damaging the unborn child.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire-fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Nitrogen oxides (NO _x) Metal oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
4.0	2025/04/14	801078-00020	Date of first issue: 2016/07/15

cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact : Oxidizing agents

Storage

Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Packaging material : Unsuitable material: None known.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
4.0	2025/04/14	801078-00020	Date of first issue: 2016/07/15

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Orbifloxacin	113617-63-3	TWA	0.2 mg/m3 (OEB 2)	Internal
Magnesium stearate	557-04-0	TWA (Inhalable particulate matter)	10 mg/m3	ACGIH
		TWA (Respirable particulate matter)	3 mg/m3	ACGIH

Engineering measures : Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Eye/face protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

Hand protection

Material : Chemical-resistant gloves

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
4.0	2025/04/14	801078-00020	Date of first issue: 2016/07/15

Appearance	:	powder
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
4.0	2025/04/14	801078-00020	Date of first issue: 2016/07/15

Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics	:	
Particle size	:	No data available

10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes	:	Inhalation Skin contact Ingestion Eye contact
-----------------	---	--------------------------------------------------------

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	:	Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method
---------------------	---	----------------------------------------------------------------------

Components:

Orbifloxacin:

Acute oral toxicity	:	LD50 (Rat): > 3,000 mg/kg Remarks: No mortality observed at this dose. LD50 (Mouse): > 2,000 mg/kg Remarks: No mortality observed at this dose. LD50 (Dog): > 600 mg/kg Symptoms: Vomiting Remarks: No mortality observed at this dose.
---------------------	---	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
4.0	2025/04/14	801078-00020	Date of first issue: 2016/07/15

Acute inhalation toxicity	: Remarks: No data available
Acute dermal toxicity	: Remarks: No data available
Acute toxicity (other routes of administration)	: LD50 (Rat): > 200 mg/kg Application Route: Intramuscular LD50 (Mouse): 500 mg/kg Application Route: Intramuscular LD50 (Rat): 233 mg/kg Application Route: Intravenous LD50 (Mouse): 250 mg/kg Application Route: Intravenous

Magnesium stearate:

Acute oral toxicity	: LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 423 Assessment: The substance or mixture has no acute oral toxicity Remarks: Based on data from similar materials
Acute dermal toxicity	: LD50 (Rabbit): > 2,000 mg/kg Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:

Orbifloxacin:

Species	: Rabbit
Method	: Draize Test
Result	: No skin irritation

Magnesium stearate:

Species	: Rabbit
Result	: No skin irritation
Remarks	: Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Orbifloxacin:

Species	: Rabbit
Result	: Mild eye irritation

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
4.0	2025/04/14	801078-00020	Date of first issue: 2016/07/15

Method : Draize Test

Magnesium stearate:

Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Orbifloxacin:

Test Type : Maximisation Test
Exposure routes : Dermal
Species : Guinea pig
Result : Not a skin sensitizer.

Magnesium stearate:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Method : OECD Test Guideline 406
Result : negative
Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:

Orbifloxacin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: equivocal

Test Type: Mouse Lymphoma
Result: positive

Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
4.0	2025/04/14	801078-00020	Date of first issue: 2016/07/15

	Application Route: Intraperitoneal injection Result: negative
	Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Application Route: Oral Result: negative
Germ cell mutagenicity - Assessment	: Weight of evidence does not support classification as a germ cell mutagen.

Magnesium stearate:

Genotoxicity in vitro	: Test Type: In vitro mammalian cell gene mutation test Result: negative Remarks: Based on data from similar materials
	Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative Remarks: Based on data from similar materials
	Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:

Orbifloxacin:

Species	: Rat
Application Route	: Oral
Exposure time	: 2 Years
NOAEL	: 200 mg/kg body weight
Result	: negative

Species	: Mouse
Application Route	: Oral
Exposure time	: 2 Years
NOAEL	: 200 mg/kg body weight
Result	: negative

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Orbifloxacin:

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
4.0	2025/04/14	801078-00020	Date of first issue: 2016/07/15

Effects on fertility	: Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity - Parent: NOAEL: 50 mg/kg body weight Early Embryonic Development: NOAEL: 50 mg/kg body weight Result: No adverse effects
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Oral Embryo-foetal toxicity: LOAEL: 333 mg/kg body weight Result: No teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral General Toxicity Maternal: NOAEL: 20 mg/kg body weight Embryo-foetal toxicity: NOAEL: 60 mg/kg body weight Result: No effects on early embryonic development, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal body weight gain Test Type: Development Species: Dog Application Route: Oral Developmental Toxicity: LOAEL: 2.5 mg/kg body weight Result: Effects on postnatal development, Skeletal malformations
Reproductive toxicity - Assessment	: Some evidence of adverse effects on development, based on animal experiments.

Magnesium stearate:

Effects on fertility	: Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test Species: Rat Application Route: Ingestion Method: OECD Test Guideline 422 Result: negative Remarks: Based on data from similar materials
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: negative Remarks: Based on data from similar materials

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
4.0	2025/04/14	801078-00020	Date of first issue: 2016/07/15

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Orbifloxacin:

Species	: Rat
NOAEL	: 20 mg/kg
LOAEL	: 80 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Testis, Liver, Kidney, spleen

Species	: Mouse
NOAEL	: 80 mg/kg
LOAEL	: 250 mg/kg
Application Route	: Oral
Exposure time	: 3 Months

Species	: Juvenile dog
NOAEL	: 50 mg/kg
LOAEL	: 250 mg/kg
Application Route	: Oral
Exposure time	: 14 Days
Target Organs	: Heart, Bone
Symptoms	: Gastrointestinal disturbance
Remarks	: mortality observed

Species	: Juvenile dog
NOAEL	: 2 mg/kg
LOAEL	: 3 mg/kg
Application Route	: Oral
Exposure time	: 90 Days
Target Organs	: Bone
Remarks	: No significant adverse effects were reported

Species	: Dog
NOAEL	: 37.5 mg/kg
Application Route	: Oral
Exposure time	: 30 Days

Species	: Cat
NOAEL	: 7.5 mg/kg
LOAEL	: 22.5 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Symptoms	: Gastrointestinal disturbance

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
4.0	2025/04/14	801078-00020	Date of first issue: 2016/07/15

Magnesium stearate:

Species	: Rat
NOAEL	: > 100 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days
Remarks	: Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Orbifloxacin:

Ingestion	: Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash Remarks: May cause photosensitisation.
-----------	--------------------------------------------------------------------------------------------------------------------------------------------------------------

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Magnesium stearate:

Toxicity to fish	: LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	: EL50 (Daphnia magna (Water flea)): > 1 mg/l Exposure time: 47 h Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	: EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials No toxicity at the limit of solubility NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
4.0	2025/04/14	801078-00020	Date of first issue: 2016/07/15

Toxicity to microorganisms	:	Test substance: Water Accommodated Fraction
	:	Method: OECD Test Guideline 201
	:	Remarks: Based on data from similar materials
	:	EC10 (Pseudomonas putida): > 100 mg/l
	:	Exposure time: 16 h
	:	Test substance: Water Accommodated Fraction
	:	Remarks: Based on data from similar materials

Persistence and degradability

Components:

Magnesium stearate:

Biodegradability	:	Result: Not biodegradable
	:	Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Magnesium stearate:

Partition coefficient: n-octanol/water	:	log Pow: > 4
----------------------------------------	---	--------------

Mobility in soil

No data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues	:	Do not dispose of waste into sewer.
	:	Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal.
	:	If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
4.0	2025/04/14	801078-00020	Date of first issue: 2016/07/15

Labels : Not applicable
Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo aircraft) : Not applicable
Packing instruction (passenger aircraft) : Not applicable

IMDG-Code

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
EmS Code : Not applicable
Marine pollutant : no

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

GB 6944/12268

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Marine pollutant : no

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

National regulatory information

Law on the Prevention and Control of Occupational Diseases

Regulations on Safety Management of Hazardous Chemicals

Catalogue of Hazardous Chemicals : This product is not listed in the catalogue of hazardous chemicals, but it meets the definition of hazardous chemicals and its principles of determination.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
4.0	2025/04/14	801078-00020	Date of first issue: 2016/07/15

Identification of Major Hazard Installations for Hazardous Chemicals (GB 18218) : Not listed

Hazardous Chemicals for Priority Management under SAWS : Not listed

Catalogue of Specially Controlled Hazardous Chemicals : Not listed

List of Explosive Precursors : Not listed

Regulations on Labour Protection in Workplaces where Toxic Substances are Used

Catalogue of Highly Toxic Chemicals : Not listed

Regulation of Environmental Management on the First Import of Chemicals and the Import and Export of Toxic Chemicals

China Severely Restricted Toxic Chemicals for Import and Export : Not listed

Regulation on the Administration of Precursor Chemicals

Catalogue and Classification of Precursor Chemicals : Not listed

Yangtze River Protection Law

This product does not contain any dangerous chemicals prohibited for inland river transport.

Regulations of Ozone Depleting Substances Management

List of Controlled Ozone Depleting Substances Import and Export : Not listed

List of Controlled Ozone Depleting Substances : Not listed

Environmental Protection Law

List of Priority Controlled Chemicals : Not listed

List of Key Controlled New Pollutants : Not listed

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 2025/04/14

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
4.0	2025/04/14	801078-00020	Date of first issue: 2016/07/15

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Orbifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
4.0	2025/04/14	801078-00020	Date of first issue: 2016/07/15

to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN